Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Boryung Corporation (003850.KS)
KRW8,070.00
-130.00 (-1.59%)
KR KSC Healthcare Medical - Pharmaceuticals
Address
Boryeong Building 3127
Seoul, KR
Seoul, KR
CEO
Jeong-Gyun Kim
Website
boryung.co.kr
IPO
2000-01-04
ISIN KR7003850005
Description
Boryung Corporation engages in the manufacture and sale of pharmaceutical products in South Korea and internationally. It offers prescription drugs for hypertension, dyslipidemia, and diabetes drugs. The company was formerly known as Boryung Pharmaceutical Co., Ltd. and changed its name to Boryung Corporation in March 2022. Boryung Corporation was founded in 1957 and is headquartered in Seoul, South Korea.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
KRW8,070.00
-130.00 (-1.59%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
166.9K
Beta
0.32
Float Shares
28.29M
Free Float %
33.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.20% | -4.75% | -10.52% | -9.35% | +0.89% | -3.53% | +3.32% | +0.56% | -51.26% | +0.43% | +1,153.06% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
8,070.00
DCF (Unlevered)
11,344.37
+40.6%
DCF (Levered)
40,789.57
+405.4%
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-02 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
2.69
Grey zone
Piotroski F-Score
5 / 9
Average
MOAT Score
6 / 10
Developing
Composite Rating
B+
Overall Score
3 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
2 / 5
Medium
P/E Score
3 / 5
Medium
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +7.4%+0.0% Q1'26: +6.2% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +24.4%-5.8% Q1'26: +9,585.7% (vs Q1'25)
-
FCF margin Drug Manufacturers - Specialty & Generic: +39.1%+9.8% Q1'26: +11.8% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +12.5%+6.4% Q1'26: +7.9% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +7.4%+6.4% Q1'26: +6.9% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+22.5% Q1'26: +25.2% (vs Q1'25)
-
Debt / EBITDA Drug Manufacturers - Specialty & Generic: -0.04×3.04× ★ Q1'26: 2.30× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
401.35B
est: 404.28B (-0.7%)
|
409.14B
est: 416.37B (-1.7%)
|
422.72B
est: 429.82B (-1.7%)
|
460.40B
est: 461.80B (-0.3%)
|
524.27B
est: 509.88B (+2.8%)
|
561.87B
est: 541.40B (+3.8%)
|
627.28B
est: 601.00B (+4.4%)
|
760.48B
est: 730.48B (+4.1%)
|
859.63B
est: 847.20B (+1.5%)
|
1.02T
est: 1.04T (-2.4%)
|
1.02T
est: 1.04T (-1.8%)
|
1.06T
1.06T – 1.06T
+2.1% YoY
|
1.08T
1.08T – 1.08T
+2.5% YoY
|
1.13T
1.13T – 1.13T
+4.1% YoY
|
| EBITDA |
41.77B
est: 50.92B (-18.0%)
|
43.98B
est: 52.44B (-16.1%)
|
93.62B
est: 54.13B (+72.9%)
|
45.36B
est: 58.16B (-22.0%)
|
62.70B
est: 64.22B (-2.4%)
|
66.95B
est: 68.19B (-1.8%)
|
81.82B
est: 75.69B (+8.1%)
|
105.72B
est: 92.00B (+14.9%)
|
110.24B
est: 106.70B (+3.3%)
|
114.81B
est: 128.63B (-10.7%)
|
108.59B
est: 127.85B (-15.1%)
|
130.58B
130.58B – 130.58B
+2.1% YoY
|
133.85B
133.85B – 133.85B
+2.5% YoY
|
139.37B
139.37B – 139.37B
+4.1% YoY
|
| EBIT |
28.99B
est: 31.35B (-7.5%)
|
28.66B
est: 32.28B (-11.2%)
|
77.37B
est: 33.33B (+132.1%)
|
29.22B
est: 35.81B (-18.4%)
|
45.27B
est: 39.53B (+14.5%)
|
39.39B
est: 41.98B (-6.2%)
|
49.74B
est: 46.60B (+6.7%)
|
69.15B
est: 56.64B (+22.1%)
|
65.85B
est: 65.69B (+0.2%)
|
71.96B
est: 79.51B (-9.5%)
|
65.07B
est: 79.03B (-17.7%)
|
80.71B
80.71B – 80.71B
+2.1% YoY
|
82.73B
82.73B – 82.73B
+2.5% YoY
|
86.14B
86.14B – 86.14B
+4.1% YoY
|
| Net Income |
20.30B
est: 27.21B (-25.4%)
|
5.61B
est: 19.57B (-71.3%)
|
56.70B
est: 76.69B (-26.1%)
|
20.31B
est: 21.33B (-4.8%)
|
32.22B
est: 38.52B (-16.4%)
|
26.86B
est: 31.29B (-14.2%)
|
43.04B
est: 42.54B (+1.2%)
|
41.89B
est: 54.50B (-23.1%)
|
40.20B
est: 46.24B (-13.1%)
|
69.63B
est: 94.36B (-26.2%)
|
64.30B
est: 34.84B (+84.6%)
|
64.81B
64.81B – 64.81B
+86.0% YoY
|
66.74B
66.74B – 66.74B
+3.0% YoY
|
76.56B
76.56B – 76.56B
+14.7% YoY
|
| SGA |
70.62B
est: 48.63B (+45.2%)
|
79.07B
est: 50.08B (+57.9%)
|
93.19B
est: 51.70B (+80.3%)
|
80.87B
est: 55.55B (+45.6%)
|
77.32B
est: 61.33B (+26.1%)
|
74.89B
est: 65.12B (+15.0%)
|
89.46B
est: 72.29B (+23.8%)
|
92.02B
est: 87.86B (+4.7%)
|
92.06B
est: 101.90B (-9.7%)
|
99.08B
est: 117.94B (-16.0%)
|
99.58B
est: 117.23B (-15.1%)
|
119.73B
119.73B – 119.73B
+2.1% YoY
|
122.73B
122.73B – 122.73B
+2.5% YoY
|
127.79B
127.79B – 127.79B
+4.1% YoY
|
| EPS |
334.64
est: 397.19 (-15.7%)
|
103.09
est: 285.66 (-63.9%)
|
988.65
est: 1,119.46 (-11.7%)
|
358.87
est: 311.32 (+15.3%)
|
569.48
est: 562.27 (+1.3%)
|
452.86
est: 456.77 (-0.9%)
|
688.72
est: 621.00 (+10.9%)
|
635.91
est: 795.50 (-20.1%)
|
610.38
est: 675.00 (-9.6%)
|
1,020.00
est: 1,124.00 (-9.3%)
|
765.85
est: 415.00 (+84.5%)
|
772.00
772.00 – 772.00
+86.0% YoY
|
795.00
795.00 – 795.00
+3.0% YoY
|
912.00
912.00 – 912.00
+14.7% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-28 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-27 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-26 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-22 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-21 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-20 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-19 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-18 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-14 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 |
| 2026-04-30 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-29 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-28 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-27 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-24 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-23 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-22 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-21 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-15 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-14 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-13 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-10 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
132.37B
OE per share TTM
1,601.85
Owner's Yield
17.11%
Maintenance CapEx ratio
6.35%
Maint CapEx / Avg PPE
29.5%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
39.55M
Shares Outstanding
84.48M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Daniel Chang | Chief Executive Officer of Pharma Biz | — | — |
| Jung-Gyun Kim | Chairman & Chief Executive Officer | — | male |
| Sung Jin Kim | Chief Strategy Officer & Director | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 003850.KS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
